相关实验视频
Updated: Nov 12, 2025

08:50
Assessment of Vascular Function in Patients With Chronic Kidney Disease
Published on: June 16, 2014
16.5K
慢性病中的心血管疾病:病理生理学见解和治疗选择
Joachim Jankowski1,2, Jürgen Floege3, Danilo Fliser4
1Institute for Molecular Cardiovascular Research (J.J.), University Hospital, Rheinisch-Westfälische Technische Hochschule Aachen (RWTH), Aachen, Germany.
Circulation
|March 15, 2021
概括
患有慢性病 (CKD) 的患者面临显著更高的心血管风险,特别是在晚期. 死亡的主要原因是心血管疾病, 而不是功能衰竭, 这凸显了针对性干预的迫切需要.
科学领域:
- 肝脏病学
- 心脏病学
- 内部医学
背景情况:
- 患有慢性病 (CKD) 的患者患心脏衰竭和突然心脏死亡等心血管事件的风险大大增加.
- 这种风险随着CKD的进展而显著升级,特别是在晚期CKD (CKD4-5阶段).
研究的目的:
- 总结目前对CKD患者心血管疾病 (CVD) 的理解.
- 在高危人群中概述心血管疾病的临床后果.
主要方法:
- 这篇文章是综合现有研究和临床知识的概述.
- 它侧重于将慢性病与心血管病理联系起来的机制.
主要成果:
- 导致慢性炎症,加速心血管衰老.
- 病理变化包括动脉样硬化,血管和心肌化,血管衰老和心肌纤维化.
结论:
- 心血管疾病是晚期慢性病死亡的主要原因,超过末期病.
- 慢性病加速心血管衰老,因此需要在治疗中关注心血管健康.
相关概念视频
Chronic Kidney Disease III: Interprofessional Care
189
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
189
Chronic Kidney Disease I: Introduction
344
Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
344
Chronic Kidney Disease IV: Nursing Management
132
Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of...
132
Chronic Kidney Disease II: Clinical Manifestations
284
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
284
Heart Failure Drugs: Diuretics
596
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
596
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
657
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
657

